Brevan Howard Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brevan Howard Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,954	Closed	-$562K	–	2112
2026 Q1	$562K	Sell	9,954 -10,076	-50%	-$587K	0.01%	1225
2025 Q4	$1.19M	Sell	20,030 -2,175	-10%	-$118K	0.01%	688
2025 Q3	$1.2M	Buy	+22,205	New	+$1.27M	0.01%	813
2024 Q4	–	Sell	-9,218	Closed	-$648K	–	1063
2024 Q3	$648K	Buy	+9,218	New	+$771K	﹤0.01%	613
2024 Q2	–	Sell	-9,197	Closed	-$803K	–	1081
2024 Q1	$803K	Buy	+9,197	New	+$823K	0.01%	322

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brevan Howard Capital Management's BMRN Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 9,954 shares — an estimated $562K sold.

Brevan Howard Capital Management first reported a position in BMRN in Q1 2024 and held it in 5 quarters. The position peaked at $1.2M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Brevan Howard Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 9,954 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $562K.
Brevan Howard Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 5 quarters.
Brevan Howard Capital Management's BioMarin Pharmaceuticals position peaked at $1.2M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.